|Bid||3.64 x 1000|
|Ask||4.77 x 8300|
|Day's Range||3.77 - 4.03|
|52 Week Range||1.47 - 5.68|
|PE Ratio (TTM)||-3.59|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.83|
On a per-share basis, the San Diego-based company said it had a loss of 24 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
ProTmune™ PROTECT Safety Data Expected in Mid-2017. Launched First-in-Human Clinical Trial of FATE-NK100 for Acute Myelogenous Leukemia. IND Cleared by FDA for FATE-NK100 with Monoclonal Antibody Therapy ...
SAN DIEGO, May 10, 2017-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...